Who Owns Immunome Stock?
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 102.85%
- Institutions (% of float)
- 109.78%
- Held by insiders
- 6.32%
- Institutional holders
- 288
- Institutions 93.7%
- Insiders 6.3%
- Public and other 0.0%
Who owns Immunome stock?
Institutional investors own about 102.8% of Immunome's shares, spread across 288 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.32% of IMNM.
The largest institutional holders are T. Rowe Price Investment Management, Inc. (17.32%), FMR, LLC (14.96%) and Blackrock Inc. (7.75%). Together, the top 10 institutions control 68.8% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their IMNM positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of IMNM
| Institution | Shares | % Held | Change |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 19.68M | 17.32% | +20.2% |
| FMR, LLC | 16.99M | 14.96% | +0.1% |
| Blackrock Inc. | 8.81M | 7.75% | +7.8% |
| State Street Corporation | 5.49M | 4.84% | +1.8% |
| Wellington Management Group, LLP | 5.21M | 4.59% | +10.1% |
| Redmile Group, LLC | 4.91M | 4.32% | -11.6% |
| Primecap Management Company | 4.58M | 4.03% | -4.3% |
| Vanguard Capital Management LLC | 4.55M | 4.01% | +2.7% |
| Driehaus Capital Management, LLC | 4.35M | 3.83% | +6.0% |
| Enavate Sciences Gp, LLC | 3.61M | 3.18% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of IMNM
| Fund | Shares | % Held |
|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 7.18M | 6.32% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.90M | 4.32% |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.91M | 3.44% |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.70M | 3.26% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.69M | 3.25% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 3.39M | 2.99% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22M | 2.84% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.16M | 2.78% |
| iShares Trust-iShares Russell 2000 ETF | 2.70M | 2.38% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.13M | 1.88% |
Frequently asked questions
Who is the largest shareholder of Immunome?
T. Rowe Price Investment Management, Inc. is the largest institutional shareholder of IMNM, owning 17.32% of shares outstanding (19.68M shares) as of its latest 13F filing.
What percentage of Immunome is owned by institutions?
Institutions own about 102.8% of IMNM shares and 109.8% of the public float.
How much of Immunome do insiders own?
Insiders, such as officers and directors, own about 6.32% of IMNM shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.